P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits
This article was originally published in The Tan Sheet
Executive Summary
A P&G petition revives the firm’s argument that future OTC proton pump inhibitors should be held to the same labeling language as Prilosec OTC. The firm also argues that the NDA process can allow labeling that unfairly gives some products marketplace advantages over category competitors.